
KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074
KBP-5074, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Under Evaluation for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease (CKD) Patients Top Line Data Expected Fourth Quarter 2020 PRINCETON, N.J., May 20, 2020 ( …